Abstract

In this study, the therapeutic role of edaravone dexborneol injection in acute ischemic stroke and its influence on nerve function were analyzed. We selected 123 acute ischemic stroke individuals admitted from December 2018 to December 2022 and grouped them based on different therapies into control and research groups. The control group (n=56) received conventional (alteplase) treatment while the research group (n=67) received edaravone dexborneol injection. The two groups were comparatively analysed for therapeutic effects, side effects of medication such as nausea, vomiting, chest tightness, fever, dizziness and headache. Similarly, the nerve function, disability degree were assessed according to the National Institutes of Health Stroke Scale and modified Rankin Scale respectively. Activities of daily living ability was evaluated using Barthel index and serum indices such as nitric oxide, endothelin-1 and matrix metalloproteinase were analysed. After analysis, the research group was found to have an evidently higher total effective rate than the control group, with equivalent side effects of medication. Marked reductions in National Institutes of Health Stroke Scale, modified Rankin Scale, endothelin-1 and matrix metalloproteinase were observed in the research group after treatment, which were notably lower than the pre-treatment levels in the control group; while the Barthel index score and nitric oxide level were statistically elevated after treatment, higher than the pre-treatment level and the control group. Conclusively, edaravone dexborneol injection is conducive to enhance the therapeutic effects with mild side effects of medication, which helps to improve patients’ nerve function, reduce the risk of disability and enhance their daily life activities, the mechanism of which may be partly associated with the regulation of serum nitric oxide, endothelin-1 and matrix metalloproteinase levels.